HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY

摘要/项目摘要：HEP DART 2021：肝病药物开发的前沿 Hep Dart：肝病药物开发的前沿是一个独立的两年一次的会议，吸引了 在过去的24年里，每次会议至少有250人参加。Hep Dart对任何对治疗感兴趣的人开放 病毒性肝炎和慢性肝病。这次会议的内容主要是为了引起人们的兴趣。 科学家和临床研究人员，专注于药物开发和疫苗学。HEP DART的目的 2021年将汇集临床医生、研究人员、基础科学家、护士、医生助理和倡导者 共同促进我们对病毒性肝炎治疗中正在进行的药物开发过程的了解 非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)。 Hep Dart将独特地融合生物、化学、药理学和临床研究领域，为 科学界对治疗学当前和未来的挑战有了更多的了解 肝脏感染、疾病和癌症。目标：(1)重点介绍抗病毒药物的研究进展 肝炎，如乙肝病毒、丙型肝炎病毒和HDV。(2)评估消除乙肝病毒和丙型肝炎病毒的进展情况 新冠肺炎大流行背景下的公共卫生威胁。(3)描述乙肝病毒的最新发展 治疗策略，包括综合治疗治愈。(4)重点介绍免疫力、照明弹、 免疫治疗和治疗策略。(5)重点介绍抗NASH、NAFLD、纤维化药物开发进展 还有肝癌。(6)描述病毒性肝炎、肝病和治疗结果的新生物标记物。(7)检讨 最新发现与新冠肺炎和肝病有关。(8)回顾当前的治疗和疫苗接种情况 病毒性肝炎指南；描述改进治疗方案的进展。(九)检视近期工作 以及预防丙型肝炎病毒感染的疫苗的未来方向。(10)了解感染乙肝病毒的后果 和NASH在儿科和青少年人群中。(11)评估治疗性疫苗在未来的作用 病毒性肝炎、非酒精性肝炎和艾滋病毒混合感染的治疗。(12)了解流行病学和 病毒性肝炎的发病机制包括HBVHDV、丙型肝炎病毒、甲型肝炎病毒和戊型肝炎病毒。(13)了解医院内的治疗方法 与艾滋病毒和其他病毒混合感染的背景。方法：HEP DART 2021包括四天内- 个人科学演示文稿，通过非并发以口头和海报演示文稿格式提供 会话。主要会议和主旨演讲者也将在会议结束后不久录制和播放。 埃默里大学继续医学教育办公室将为AMA指定1类学分 医生认可奖授予这一认证项目。Hep Dart提供了一种轻松和科学的 营造博士生和博士生相互交流、共同学习的氛围。请求支持以提供帮助 支付青年调查人员、妇女、可见的少数族裔和其他未成年妇女的奖学金和旅行补助金费用 代表代表。

Abstract/ Project summary: HEP DART 2021: Frontiers in Drug Development for Hepatology HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees per meeting for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2021 is to assemble clinicians, researchers, basic scientists, nurses, physician assistants and advocates together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Evaluate the progress toward the elimination of HBV and HCV as public health threats in the context of the COVID-19 pandemic. (3) Describe the latest developments in HBV curative strategies, including combination therapy for cure. (4) Highlight the latest findings in immunity, flares, immunotherapy and cure strategies. (5) Highlight advances in drug development against NASH, NAFLD, fibrosis and HCC. (6) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (7) Review the latest findings related to COVID-19 and liver disease. (8) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (9) Examine recent work and future directions for vaccines to prevent HCV infection. (10) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (11) Assess the role of therapeutic vaccines in future therapies for viral hepatitis, NASH, and co-infections with HIV. (12) Understand the epidemiology and pathogenesis of viral hepatitis including HBV-HDV, HCV, HAV and HEV. (13) Understand treatment in the context of co-infection with HIV and other viruses. METHODS: HEP DART 2021 comprises four days of in- person scientific presentations, delivered in both oral and poster presentations formats via non-concurrent sessions. Main sessions and keynote speakers will also be taped and streamed virtually shortly after the meeting. Emory University, Office of Continuing Medical Education will designate category 1 credits toward the AMA Physician’s Recognition Award to this accredited program. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under- represented delegates.